X

Trial Profile

Mass Balance, Pharmacokinetics, and Metabolism of [^14C]-Alisertib in Patients With Advanced Solid Tumors or Lymphomas

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alisertib (Primary)
Indications Bladder cancer; Lymphoma; Mesothelioma; Ovarian cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Millennium

Most Recent Events

07 Jan 2020 Results of metabolic profiling, published in the Drug Metabolism and Disposition.
06 Nov 2018 Results published in the Investigational New Drugs
23 Oct 2013 Results for part A presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com